Cargando…

Met and its ligand HGF are associated with clinical outcome in breast cancer

Few biomarkers exist to predict radiotherapy response in breast cancer. In vitro studies suggest a role for Met and its ligand HGF. To study this suggested role, MET and HGF gene copy numbers were determined by droplet digital PCR in tumours from 205 pre-menopausal and 184 post-menopausal patients,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veenstra, Cynthia, Pérez-Tenorio, Gizeh, Stelling, Anna, Karlsson, Elin, Mirwani, Sanam Mirwani, Nordensköljd, Bo, Fornander, Tommy, Stål, Olle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095065/ https://www.ncbi.nlm.nih.gov/pubmed/27175600 http://dx.doi.org/10.18632/oncotarget.9268

Ejemplares similares

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype
por: Veenstra, Cynthia, et al.
Publicado: (2019)

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
por: Karlsson, Elin, et al.
Publicado: (2018)

IP6K2 predicts favorable clinical outcome of primary breast cancer
por: Sandström, Josefine, et al.
Publicado: (2021)

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
por: Karlsson, Elin, et al.
Publicado: (2013)

Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast‐conserving surgery: a long‐term follow‐up of the SweBCG91‐RT randomised trial
por: Sjöström, Martin, et al.
Publicado: (2020)

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
por: Dar, Huma, et al.
Publicado: (2021)

EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer
por: Husa, Anna-Maria, et al.
Publicado: (2016)

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
por: Hilborn, Erik, et al.
Publicado: (2014)

Akt kinases in breast cancer and the results of adjuvant therapy
por: Stål, Olle, et al.
Publicado: (2003)

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
por: Johansson, Annelie, et al.
Publicado: (2022)

Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2−Negative Postmenopausal Breast Cancer Patients
por: Pousette, Jenny, et al.
Publicado: (2022)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

ERBB2 and PTPN2 gene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab
por: Ellegård, Sander, et al.
Publicado: (2019)

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
por: Hilborn, Erik, et al.
Publicado: (2016)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010)

HGF-MET as a breast cancer biomarker
por: Liu, Shuying
Publicado: (2015)

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
por: Sivik, Tove, et al.
Publicado: (2012)

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Schroeder, Brock, et al.
Publicado: (2017)

HGF/c-MET Signaling in Melanocytes and Melanoma
por: Czyz, Malgorzata
Publicado: (2018)

HGF–Met Pathway in Regeneration and Drug Discovery
por: Matsumoto, Kunio, et al.
Publicado: (2014)

HGF/Met Axis in Heart Function and Cardioprotection
por: Gallo, Simona, et al.
Publicado: (2014)

Physiological Signaling and Structure of the HGF Receptor MET
por: Baldanzi, Gianluca, et al.
Publicado: (2014)

HGF/MET Signaling in Malignant Brain Tumors
por: Mulcahy, Elizabeth Qian Xu, et al.
Publicado: (2020)

Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion
por: Cao, Hui-Hui, et al.
Publicado: (2015)

Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy
por: Prat, Maria, et al.
Publicado: (2014)

HGF-independent Potentiation of EGFR Action by c-Met
por: Dulak, Austin M., et al.
Publicado: (2011)

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
por: Venepalli, Neeta K., et al.
Publicado: (2013)

The role of HGF/c-MET signaling pathway in lymphoma
por: Lam, Bao Quoc, et al.
Publicado: (2016)

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
por: Papaccio, Federica, et al.
Publicado: (2018)

Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
por: Cruickshanks, Nichola, et al.
Publicado: (2017)

Cyclic Peptide-Based Biologics Regulating HGF-MET
por: Sato, Hiroki, et al.
Publicado: (2020)

The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
por: Wang, Haiyu, et al.
Publicado: (2020)

Targeting HGF/c-MET Axis in Pancreatic Cancer
por: Pothula, Srinivasa P., et al.
Publicado: (2020)

The Role of HGF/MET Signaling in Metastatic Uveal Melanoma
por: Tanaka, Ryota, et al.
Publicado: (2021)

HGF and MET: From Brain Development to Neurological Disorders
por: Desole, Claudia, et al.
Publicado: (2021)

Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway
por: Vallet, Sonia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ed6e0526s9c74nomruipdqavln